PMID- 12220963
OWN - NLM
STAT- MEDLINE
DCOM- 20030314
LR  - 20190922
IS  - 1043-6618 (Print)
IS  - 1043-6618 (Linking)
VI  - 46
IP  - 3
DP  - 2002 Sep
TI  - Folic acid and vitamin B(12) supplementation attenuates isoprenaline-induced 
      myocardial infarction in experimental hyperhomocysteinemic rats.
PG  - 213-19
AB  - Hyperhomocysteinemia (Hhcy) is an independent risk factor for cardiovascular 
      disease. Oxidative stress may contribute to the deleterious effects of 
      homocysteine (Hcy). The aim of the present study is to study the effect of folic 
      acid and Vitamin B(12) supplementation on isoprenaline (ISO)-induced myocardial 
      infarction (MI) in hyperhomocysteinemic rats. Hhcy was induced by daily intake of 
      methionine (1 g kg(-1) body weight) in the drinking water for 4 weeks. MI was 
      then produced by a single subcutaneous injection of ISO (300 mg kg(-1), s.c.). 
      Electrocardiographic parameters, heart rate, ST segment, and blood pressure as 
      well as serum marker enzymes, creatine kinase (CK) and lactate dehydrogenase 
      (LDH) were measured. Lipid peroxidation measured as malondialdehyde (MDA) and 
      reduced glutathione (GSH) concentrations in heart tissue were estimated as 
      indices of oxidative stress. Hhcy resulted in significant blood pressure 
      reduction, ST segment elevation and increase in heart rate and serum CK and LDH 
      levels. Cardiac MDA was significantly increased, while GSH was decreased in Hhcy 
      group compared to the normal control group. All the measured parameters were 
      greatly exaggerated in Hhcy rats treated with ISO in comparison with Hhcy rats 
      alone. Administration of folic acid (10 mg kg(-1), orally via gavage) and Vitamin 
      B(12) (500 microg kg(-1), i.m.) concurrently for 4 weeks during the induction of 
      Hhcy markedly reduced the increase in heart rate, ST segment elevation and blood 
      pressure reduction as well as the increase in serum CK and LDH levels. Cardiac 
      MDA content was decreased while cardiac GSH was elevated in the treated group 
      compared to Hhcy + ISO group. Moreover, the severe cardiac histopathological 
      changes observed in Hhcy + ISO group were attenuated by folic acid and Vitamin 
      B(12). These results suggest that Hhcy aggravates MI via oxidative stress 
      mechanisms and that lowering Hcy level with folic acid and Vitamin B(12) can 
      ameliorate the detrimental effects of Hhcy and may reduce the risk of MI.
CI  - Copyright 2002 Elsevier Science Ltd.
FAU - Hagar, Hanan H
AU  - Hagar HH
AD  - Department of Pharmacology, College of Medicine & KHUH, King Saud University, PO 
      Box 2925, Riyadh 11461, Saudi Arabia. hananhager@yahoo.com
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 935E97BOY8 (Folic Acid)
RN  - AE28F7PNPL (Methionine)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - GAN16C9B8O (Glutathione)
RN  - L628TT009W (Isoproterenol)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - Animals
MH  - Blood Pressure/drug effects
MH  - Creatine Kinase/blood/drug effects
MH  - Folic Acid/*pharmacology/therapeutic use
MH  - Glutathione/metabolism
MH  - Heart Rate/drug effects
MH  - Hemodynamics/drug effects
MH  - Hyperhomocysteinemia/*prevention & control
MH  - Isoproterenol/administration & dosage
MH  - L-Lactate Dehydrogenase/blood/drug effects
MH  - Lipid Peroxidation/drug effects
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Methionine/administration & dosage
MH  - Myocardial Infarction/chemically induced/*prevention & control
MH  - Myocardium/pathology
MH  - Oxidative Stress/drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Vitamin B 12/*pharmacology/therapeutic use
EDAT- 2002/09/11 10:00
MHDA- 2003/03/15 04:00
CRDT- 2002/09/11 10:00
PHST- 2002/09/11 10:00 [pubmed]
PHST- 2003/03/15 04:00 [medline]
PHST- 2002/09/11 10:00 [entrez]
AID - S1043661802000956 [pii]
AID - 10.1016/s1043-6618(02)00095-6 [doi]
PST - ppublish
SO  - Pharmacol Res. 2002 Sep;46(3):213-19. doi: 10.1016/s1043-6618(02)00095-6.